Summary by Futu AI
Clover Biopharmaceuticals Limited (“Clover Biologics”) announced on December 29, 2023 that its development of SCB-219M, a targeted drug for tumor chemotherapy-associated thrombocytopenia (CIT), received positive data in a Phase I clinical trial. The trial is a multi-center, open-label, dose-climbing, and dose-escalation study to explore the safety, tolerability, immunogenicity, and pharmacokinetic properties of SCB-219M injected subcutaneously in patients with CIT. Preliminary results showed that all cancer patients treated with the drug (a total of 9 cases) maintained or restored platelet counts after one week, and efficacy lasted for at least three weeks. In addition, SCB-219M demonstrated good safety and tolerability, with no serious adverse events or dose-limiting toxicity observed. Clover Biologics plans to launch Phase Ib clinical trials...Show More